Aadi Bioscience, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
Whitehawk Therapeutics divests its FYARRO business to focus on developing a portfolio of antibody-drug conjugates (ADCs) targeting various cancers.
Aadi Bioscience's recent SEC filing outlines the company's common stock details, preferred stock authorization, pre-funded warrants, and anti-takeover provisions.